Calamos Advisors LLC Sells 1,335 Shares of Zoetis Inc. (NYSE:ZTS)

Calamos Advisors LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 206,671 shares of the company’s stock after selling 1,335 shares during the period. Calamos Advisors LLC’s holdings in Zoetis were worth $40,791,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Blue Bell Private Wealth Management LLC boosted its stake in Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after acquiring an additional 112 shares in the last quarter. VitalStone Financial LLC acquired a new stake in Zoetis in the first quarter valued at approximately $37,000. Evermay Wealth Management LLC boosted its stake in Zoetis by 439.3% in the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Finally, Worth Asset Management LLC acquired a new stake in Zoetis in the first quarter valued at approximately $26,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

NYSE:ZTS traded up $1.17 during mid-day trading on Thursday, hitting $153.11. The company’s stock had a trading volume of 4,729,915 shares, compared to its average volume of 2,988,848. Zoetis Inc. has a 1 year low of $148.48 and a 1 year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The stock has a market cap of $70.03 billion, a price-to-earnings ratio of 30.15, a PEG ratio of 2.34 and a beta of 0.85. The business’s fifty day moving average is $177.35 and its two-hundred day moving average is $180.39.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. During the same period in the previous year, the company earned $1.15 earnings per share. The company’s revenue was up 8.5% compared to the same quarter last year. Analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.13%. Zoetis’s payout ratio is 34.12%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ZTS shares. Barclays boosted their target price on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. The Goldman Sachs Group boosted their price objective on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Finally, Piper Sandler reissued an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $221.75.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the sale, the executive vice president now owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.12% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.